Patent classifications
G01N2333/01
DETECTION AND SEQUENCING OF FRAGMENTED DNA
The present invention provides modified single primer extension-based methods for generating an amplified library of fragments of a target gene or genome of interest from a sample of fragmented DNA, wherein the library is suitable for use in detecting, quantifying and/or sequencing the target gene or genome of interest. The present invention also provides compositions for use in such methods. In some embodiments the present invention provides methods and compositions specifically for detecting, quantifying and/or sequencing circulating tumor derived HPV DNA.
Phage-mediated immunoassay and methods for determining susceptibility of bacteria to antibiotic or probiotic agents
Methods for determining the susceptibility or resistance of bacteria to antibiotic agents are provided. In one embodiment, the methods include culturing the bacteria in the presence or absence or the antimicrobial agent to generate a primary culture which is then cultured in the presence or absence of transforming phages. The recombinant phages are specific to the bacteria and comprise a heterologous marker (e.g., a nucleic acid that is expressible as a detectable product such as an RNA or a protein). The susceptibility or resistance of the bacteria to the antimicrobial agent may be determined by assaying the culture for the presence or absence of the heterologous marker, wherein a reduction in the level or activity of the marker in the culture compared to the level or activity of the marker in a comparative culture indicates that the bacteria is sensitive to the antibiotic agent.
Dynamic Modification of Bioaerosol Detection with Genetic Identification
A bioaerosol detector is operated in accordance with one or more first inputs. Operating the bioaerosol detector includes filtering pathogens from the air, extracting genetic material from the filtered pathogens, and analyzing the extracted genetic material to identify the filtered pathogens. While operating the bioaerosol detector in accordance with the one or more first inputs, a change is identified in an operating condition for the bioaerosol detector. In response, the bioaerosol detector is operated in accordance with one or more second inputs. At least one input of the one or more second inputs is distinct from a respective input of the one or more first inputs.
Dynamic modification of bioaerosol detection with genetic identification
A bioaerosol detector is operated in accordance with one or more first inputs. Operating the bioaerosol detector includes filtering pathogens from the air, extracting genetic material from the filtered pathogens, and analyzing the extracted genetic material to identify the filtered pathogens. While operating the bioaerosol detector in accordance with the one or more first inputs, a change is identified in an operating condition for the bioaerosol detector. In response, the bioaerosol detector is operated in accordance with one or more second inputs. At least one input of the one or more second inputs is distinct from a respective input of the one or more first inputs.
IMMUNOTHERAPY FOR POLYOMAVIRUSES
Provided herein are methods and compositions related to polyomavirus epitopes useful in the treatment of cancer or a polyomavirus infection.
LIPID BILAYER-INTEGRATED SPP1 CONNECTOR PROTEIN NANOPORE AND SPP1 CONNECTOR PROTEIN VARIANTS FOR USE AS LIPID BILAYER-INTEGRATED NANOPORE
A conductive channel-containing membrane includes a membrane layer, and a SPP1 connector polypeptide variant that is incorporated into the membrane layer to form an aperture through which conductance can occur when an electrical potential is applied across the membrane. A method of sensing a molecule, such as a polypeptide or nucleic acid molecule, makes use of the conductive channel-containing membrane. A method of DNA sequence makes use of the conductive channel-containing membrane.
Rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate
African swine fever virus (ASFV) is the etiological agent of a contagious, often lethal viral disease of domestic pigs. The control of African Swine Fever (ASF) has been hampered by the unavailability of vaccines. Experimental vaccines have been derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFVs; however, these vaccines are only successful when protecting against homologous viruses. We have constructed a recombinant Δ9GL/ΔUK virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate by deleting the specific virulence-associated 9GL (B119L) and the UK (DP96R) genes. In vivo, ASFV-G Δ9GL/ΔUK administered intramuscularly to swine even at relatively high doses (10.sup.6 HAD.sub.50) does not induce disease. Importantly, animals infected with 10.sup.4 or 10.sup.6 HAD.sub.50 are solidly protected against the presentation of clinical disease when challenged at 28 days post infection with the virulent parental strain Georgia 2007.
Recombinant antigens of porcine circovirus 2 (PCV-2) for vaccine formulations, diagnostic kit and use thereof
- Márcia Rogéria De Almeida ,
- Abelardo Silva Junior ,
- Juliana Lopes Rangel Fietto ,
- Gustavo Costa Bressan ,
- Rafael Locatelli Salgado ,
- Thiago Souza Onofre ,
- Mariana Costa Fausto ,
- Pedro Marcus Pereira Vidigal ,
- Sthefany Patareli Kalks ,
- Josicelli Souza Crispim ,
- Roberta Amaziles Silva Leite ,
- Jackson de Andrade Teixeira ,
- Natália Fialho Gonzaga ,
- Tiago Jaquel Zilch ,
- Luiz Fernando Lino De Souza ,
- Amanda Martins De Cruz Souza ,
- Antônio De Morais Monteiro
The present invention relates to the preparation of the recombinant antigen of the viral capsid of Porcine circovirus 2 (PCV-2) and modifications thereof, upon expression in a prokaryotic system, purification in the monomer form, recovery of virus-like particles (VLPs) and their use in vaccine formulations, diagnostic kits and a system for quantifying in vaccine lots of the PCV-2 antigen by means of a capture ELISA assay. The antigens and vaccine formulations can be used in animal's immunization in programs for combatting PCV-2-associated diseases in conventional swine breeding systems, and represent alternatives to the commercially available vaccines. The ELISA kit can be used for testing the quality of commercial and/or experimental vaccines against PCV-2.
Porcine circovirus type 2 (PCV2), immunogenic composition containing the same, test kit, and application thereof
The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain.
METHODS FOR BACTERIOPHAGE DETECTION
Provided are methods and devices for the detection of bacteriophages.